Cargando…

Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393065/ https://www.ncbi.nlm.nih.gov/pubmed/37394664 http://dx.doi.org/10.1093/eurheartj/ehad406

Ejemplares similares

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
por: Jhund, Pardeep S., et al.
Publicado: (2022)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
por: Desai, Akshay S., et al.
Publicado: (2022)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
por: Kaplinsky, Edgardo
Publicado: (2020)

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2020)

Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
por: Wang, Xiaowen, et al.
Publicado: (2022)

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2020)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H., et al.
Publicado: (2023)

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
por: Kosiborod, Mikhail N., et al.
Publicado: (2020)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
por: Adamson, Carly, et al.
Publicado: (2022)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
por: McMurray, John J.V., et al.
Publicado: (2019)

Corrigendum to: Clinical case: heart failure and ischaemic heart disease
Publicado: (2020)

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
por: Camps-Vilaró, Anna, et al.
Publicado: (2020)

DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
por: Wagdy, Kerolos, et al.
Publicado: (2020)

Corrigendum to: Pulmonary Hypertension in Heart Failure Patients
por: Rao, Sriram D, et al.
Publicado: (2020)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

DAPA-HF study: Are the benefits uniform across non-diabetic subgroups
por: Pareek, Anil, et al.
Publicado: (2020)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
por: Marx, Nikolaus, et al.
Publicado: (2021)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Corrigendum to: Care plans for the older heart failure patient
Publicado: (2019)

Corrigendum to: Renal function, electrolytes and congestion monitoring in heart failure
Publicado: (2019)

Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry
Publicado: (2023)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c7qd9kdk60ihda8csuup86d06j